共 35 条
- [21] Patterns of PET-positive residual tissue at interim restaging and risk of treatment failure in advanced-stage Hodgkin’s lymphoma: an analysis of the randomized phase III HD18 trial by the German Hodgkin Study GroupEuropean Journal of Nuclear Medicine and Molecular Imaging, 2024, 51 : 490 - 495Justin FerdinandusLutz van HeekKatrin RothMarkus DietleinHans-Theodor EichChristian BauesPeter BorchmannCarsten Kobe
- [22] Patterns of PET positive residual tissue at early interim staging and risk of treatment failure in advanced-stage Hodgkin's Lymphoma: an analysis of the randomized phase III HD18 trial by the German Hodgkin Study GroupEUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S47 - S47Ferdinandus, J.van Heek, L.Roth, K. S.Dietlein, M.Eich, H.Baues, C.Borchmann, P.Kobe, C.
- [23] Patterns of PET-positive residual tissue at interim restaging and risk of treatment failure in advanced-stage Hodgkin's lymphoma: an analysis of the randomized phase III HD18 trial by the German Hodgkin Study GroupEUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 (02) : 490 - 495Ferdinandus, Justinvan Heek, LutzRoth, KatrinDietlein, MarkusEich, Hans-TheodorBaues, ChristianBorchmann, PeterKobe, Carsten
- [24] Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 studyHAEMATOLOGICA, 2022, 107 (05) : 1086 - 1094Evens, Andrew M.Connors, Joseph M.Younes, AnasAnsell, Stephen M.Kim, Won SeogRadford, JohnFeldman, TatyanaTuscano, JosephSavage, Kerry J.Oki, YasuhiroGrigg, AndrewPocock, ChristopherDlugosz-Danecka, MonikaFenton, KeenanForero-Torres, AndresLiu, RachaelJolin, HinaGautam, AshishGallamini, Andrea
- [25] Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trialLANCET, 2024, 404 (10450): : 341 - 352Borchmann, PeterFerdinandus, JustinSchneider, GundolfMoccia, AldenGreil, RichardHertzberg, MarkSchaub, ValdeteHuettmann, AndreasKeil, FelixDierlamm, JudithHaenel, MathiasNovak, UrbanMeissner, JuliaZimmermann, AndreasMathas, StephanZijlstra, Josee M.Fossa, AlexanderViardot, AndreasHertenstein, BerndMartin, SonjaGiri, PratyushScholl, SebastianTopp, MaxsJung, WolframVucinic, VladanBeck, Hans-JoachimKerkhoff, AndreaUnger, BenjaminRank, AndreasSchroers, RolandBueschenfelde, Christian Meyer zumde Wit, MaikeTrautmann-Grill, KarolinKamper, PeterMolin, DanielKreissl, StefanieKaul, Helenvon Tresckow, BastianBorchmann, SvenBehringer, KarolinFuchs, MichaelRosenwald, AndreasKlapper, WolframEich, Hans-TheodorBaues, ChristianZomas, AthanasiosHallek, MichaelDietlein, MarkusKobe, CarstenDiehl, Volker
- [26] Long Term Follow-up Analysis of HD9601 Trial Comparing ABVD Vs Stanford V Vs MOPPABVCAD in Patients with Newly Diagnosed Advanced Stage Hodgkin Lymphoma. A Study from the Intergruppo Italiano Linforni (IIL).BLOOD, 2008, 112 (11) : 902 - 902Chisesi, TeodoroBellei, MonicaLuminari, StefanoMarcheselli, LuigiLevis, AlessandroVitolo, UmbertoStelitano, CaterinaPavone, VincenzoMerli, FrancescoLiberati, MarinaBaldini, LucaBordonaro, RobertoPesce, EmanuelaGobbi, PaoloFederico, Massimo
- [27] Efficacy and tolerability of trabectedin in elderly patients with sarcoma: subgroup analysis from a phase III, randomized controlled study of trabectedin or dacarbazine in patients wits advanced liposarcoma or leiomyosarcomaANNALS OF ONCOLOGY, 2018, 29 (09) : 1995 - 2002Jones, R. L.Demetri, G. D.Schuetze, S. M.Milhem, M.Elias, A.Van Tine, B. A.Hamm, J.McCarthy, S.Wang, G.Parekh, T.Knoblauch, R.Hensley, M. L.Maki, R. G.Patel, S.von Mehren, M.
- [28] Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study GroupLEUKEMIA, 2022, 36 (02) : 580 - 582Damaschin, CarlaGoergen, HelenKreissl, StefaniePluetschow, AnnetteBreywisch, FrankMathas, StephanMeissner, JuliaSoekler, MartinTopp, Max S.Vucinic, VladanZimmermann, Andreasvon Tresckow, BastianFuchs, MichaelEngert, AndreasBorchmann, PeterEichenauer, Dennis A.
- [29] Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study GroupLeukemia, 2022, 36 : 580 - 582Carla DamaschinHelen GoergenStefanie KreisslAnnette PlütschowFrank BreywischStephan MathasJulia MeissnerMartin SöklerMax S. ToppVladan VucinicAndreas ZimmermannBastian von TresckowMichael FuchsAndreas EngertPeter BorchmannDennis A. Eichenauer
- [30] Treatment related organ toxicities at one year follow-up in patients with advanced stage classical Hodgkin Lymphoma: results from the randomized phase III HD21 trial by the German Hodgkin Study GroupONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 111 - 111Ferdinandus, J.Moccia, A.Greil, R.Hertzberg, M.Schaub, VHuttmann, A.Keil, F.Dierlamm, J.Haenel, M.Novak, U.Meissner, J.Zimmermann, A.Mathas, S.Zijlstra, J.Fossa, A.Viardot, A.Hertenstein, B.Martin, S.Giri, P.Kamper, P.Molin, D.Kreissl, S.Fuchs, M.Behringer, K.Schneider, G.Rosenwald, A.Klapper, W.Eich, H. -TBaues, C.Hallek, M.Dietlein, M.Kobe, C.Diehl, VEngert, A.Borchmann, P.